Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1985 Dec;28(6):839–841. doi: 10.1128/aac.28.6.839

Cerebrospinal fluid penetration of moxalactam in ventriculostomy patients.

R J Creger, R I Cowan, H S Nearman, J L Blumer, W R Selman, L H Danziger
PMCID: PMC180342  PMID: 4083867

Abstract

The cerebrospinal fluid penetration of moxalactam was simultaneously investigated in three patients with presumed bacterial meningitis. When ratios of simultaneously drawn ventriculostomy to serum moxalactam levels of 1, 2, 3, and 4 h were examined, the penetration ratios were 7.8 +/- 2.4, 11.2 +/- 1.3, 14.2 +/- 2.5, and 15.0 +/- 4.9%, respectively. These ratios were not statistically different from the penetration of moxalactam calculated by the area under the concentration-time curve technique (8.97 +/- 1.89%).

Full text

PDF
839

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bergan T. Pharmacokinetics of tissue penetration of antibiotics. Rev Infect Dis. 1981 Jan-Feb;3(1):45–66. doi: 10.1093/clinids/3.1.45. [DOI] [PubMed] [Google Scholar]
  2. Chung M. Computation of model-independent pharmacokinetic parameters during multiple dosing. J Pharm Sci. 1984 Apr;73(4):570–571. doi: 10.1002/jps.2600730436. [DOI] [PubMed] [Google Scholar]
  3. Congeni B. L. Comparison of ceftriaxone and traditional therapy of bacterial meningitis. Antimicrob Agents Chemother. 1984 Jan;25(1):40–44. doi: 10.1128/aac.25.1.40. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Crane L. R., Lerner A. M. Non-traumatic gram-negative bacillary meningitis in the Detroit Medical Center, 1964-1974; (with special mention of cases due to Escherichia coli). Medicine (Baltimore) 1978 May;57(3):197–209. doi: 10.1097/00005792-197805000-00001. [DOI] [PubMed] [Google Scholar]
  5. Fisher J. F., Carter M. J., Parsons J., Rissing J. P. Moxalactam (LY127935) in treatment of meningitis due to gram-negative bacilli. Antimicrob Agents Chemother. 1981 Feb;19(2):218–221. doi: 10.1128/aac.19.2.218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kaplan S. L., Mason E. O., Jr, Garcia H., Kvernland S. J., Loiselle E. M., Anderson D. C., Mintz A. A., Feigin R. D. Pharmacokinetics and cerebrospinal fluid penetration of moxalactam in children with bacterial meningitis. J Pediatr. 1981 Jan;98(1):152–157. doi: 10.1016/s0022-3476(81)80562-8. [DOI] [PubMed] [Google Scholar]
  7. Landesman S. H., Corrado M. L., Cherubin C. C., Gombert M., Cleri D. Diffusion of a new beta-lactam (LY 127935) into cerebrospinal fluid. Implications for therapy of gram-negative bacillary meningitis. Am J Med. 1980 Jul;69(1):92–98. doi: 10.1016/0002-9343(80)90505-7. [DOI] [PubMed] [Google Scholar]
  8. Landesman S. H., Corrado M. L., Shah P. M., Armengaud M., Barza M., Cherubin C. E. Past and current roles for cephalosporin antibiotics in treatment of meningitis. Emphasis on use in gram-negative bacillary meningitis. Am J Med. 1981 Oct;71(4):693–703. doi: 10.1016/0002-9343(81)90240-0. [DOI] [PubMed] [Google Scholar]
  9. Lüthy R., Blaser J., Bonetti A., Simmen H., Wise R., Siegenthaler W. Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime. Antimicrob Agents Chemother. 1981 Nov;20(5):567–575. doi: 10.1128/aac.20.5.567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Olson D. A., Hoeprich P. D., Nolan S. M., Goldstein E. Successful treatment of gram-negative bacillary meningitis with moxalactam. Ann Intern Med. 1981 Sep;95(3):302–305. doi: 10.7326/0003-4819-95-3-302. [DOI] [PubMed] [Google Scholar]
  11. Polk R. E., Mayhall C. G., Tartaglione T., Baggett J., Patterson P. Sequential ventricular fluid concentrations of ceftazidime--report of three cases. Drug Intell Clin Pharm. 1984 Dec;18(12):984–987. doi: 10.1177/106002808401801209. [DOI] [PubMed] [Google Scholar]
  12. Reed M. D., Aronoff S. C., Myers C. M., Husak M. P., Bertino J. S., Jr, Blumer J. L. Developmental pharmacokinetics of moxalactam. Antimicrob Agents Chemother. 1983 Sep;24(3):383–387. doi: 10.1128/aac.24.3.383. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Schaad U. B., McCracken G. H., Jr, Loock C. A., Thomas M. L. Pharmacokinetics and bacteriologic efficacy of moxalactam, cefotaxime, cefoperazone, and rocephin in experimental bacterial meningitis. J Infect Dis. 1981 Feb;143(2):156–163. doi: 10.1093/infdis/143.2.156. [DOI] [PubMed] [Google Scholar]
  14. Schaad U. B., McCracken G. H., Jr, Threlkeld N., Thomas M. L. Clinical evaluation of a new broad-spectrum oxa-beta-lactam antibiotic, moxalactam, in neonates and infants. J Pediatr. 1981 Jan;98(1):129–136. doi: 10.1016/s0022-3476(81)80559-8. [DOI] [PubMed] [Google Scholar]
  15. Smith I. L., Schentag J. J. Noncompartmental determination of the steady-state volume of distribution during multiple dosing. J Pharm Sci. 1984 Feb;73(2):281–282. doi: 10.1002/jps.2600730239. [DOI] [PubMed] [Google Scholar]
  16. Swanson D. J., Reitberg D. P., Smith I. L., Wels P. B., Schentag J. J. Steady-state moxalactam pharmacokinetics in patients: noncompartmental versus two-compartmental analysis. J Pharmacokinet Biopharm. 1983 Aug;11(4):337–353. doi: 10.1007/BF01058954. [DOI] [PubMed] [Google Scholar]
  17. Thirumoorthi M. C., Buckley J. A., Aravind M. K., Kauffman R. E., Dajani A. S. Diffusion of moxalactam into the cerebrospinal fluid in children with bacterial meningitis. J Pediatr. 1981 Dec;99(6):975–979. doi: 10.1016/s0022-3476(81)80036-4. [DOI] [PubMed] [Google Scholar]
  18. Uwaydah M., Tannir N., Kantarjian H., Osseiran M., Bal'a F. Moxalactam therapy of bacterial meningitis in adults. Antimicrob Agents Chemother. 1983 Feb;23(2):289–292. doi: 10.1128/aac.23.2.289. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES